Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X by LA Times Studios, adding:
“Lung cancer. A devastating disease when current standards of care fail. Our Quilt 2023 randomized trial in early diagnosed first-line patients and Quilt3.005 in patients who failed all standards of care was the basis of accelerated approval by the Saudi FDA.
The beginning of the paradigm change in cancer. Two randomized trials are now actively enrolling and going globally. Valerie is a beautiful example of the power of NK cells and living a long, high quality of life when all hope is lost.”
Quoting LA Times Studios’ post:
“From a prognosis of weeks to living years, witness the power of the ‘Cancer Bioshield.’ This approach leverages the body’s innate immune system to fight late-stage lung cancer, proving that maintaining ALC levels is key to longevity and quality of life.”
More posts featuring Pat Soon-Shiong.